PMEF
VIR icon

Point72 Middle East FZE’s Vir Biotechnology VIR Stock Holding History

Point72 Middle East FZE’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,698
Closed -$128K – 1275
2023
Q4 		$128K Buy
+12,698
New +$116K ﹤0.01% 1141

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Middle East FZE's VIR Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Vir Biotechnology (VIR) in Q1 2024, closing a stake of 12,698 shares — an estimated $128K sold.

Point72 Middle East FZE first reported a position in VIR in Q4 2023 and held it in 1 quarter. The position peaked at $128K in Q4 2023. 209 funds tracked by Wall St. Rank hold VIR as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Vir Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 12,698 Vir Biotechnology shares in Q1 2024, an estimated $128K.
  • Point72 Middle East FZE first reported a position in Vir Biotechnology in Q4 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Vir Biotechnology position peaked at $128K in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.